Efficacy of therapy of moderate ulcerative colitis MMX mesalazine


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Ulcerative colitis (UC) is a chronic disease characterized by immune diffuse inflammation of the mucous membrane of the colon with the obligatory involvement of the rectum in the inflammatory process. Choosing the type of conservative or surgical treatment is determined by the severity of the attack, the length of lesions of the colon, the presence of extra-intestinal manifestations, disease duration, efficacy and safety of prior therapy, and the risk of developing UC complications. In Russia and abroad, mesalazine is actively used for the treatment and prevention of recurrence of UC, because it has a minimum of side effects associated with individual intolerance to the drug. Currently, pharmacological specialized manufacturing technologies provide targeted delivery of mesalazine to the affected area, maintaining its high concentration throughout the colon.

Full Text

Restricted Access

About the authors

Oleg V. Knyazev

Moscow clinical scientific practical center

Email: o.knyazev@mknc.ru
MD, head of the Department of inflammatory bowel diseases

Nikita I. Belyakov

Moscow clinical scientific practical center

resident physician

Anna V. Kagramanova

Moscow clinical scientific practical center

PhD, senior researcher, Department of inflammatory bowel diseases

Nina A. Fadeeva

Moscow clinical scientific practical center

PhD, senior researcher, Department of inflammatory bowel diseases

Askold I. Parfenov

Moscow clinical scientific practical center

MD, professor

References

  1. Рекомендации по диагностике и лечению взрослых больных язвенным колитом. Колопроктология. 2013;3(45):4-38. [Guidelines for the diagnosis and treatment of ulcerative colitis in adults. Coloproctology. 2013;3(45):4-38 (in Russ.)]
  2. Першко А.М., Самедов Б.Х., Рукшина О.А. Неспецифический язвенный колит: диагностика и лечение. СПб., 2003. 112 с. [Pershko A.M., Samedov B.Kh., Rukshina O.A. Ulcerative colitis: diagnosis and treatment. SPb., 2003. 112 p. (in Russ.)]
  3. Sadler R.S. Epidemiology of inflammatory bowel disease. Inflammatory bowel disease: from bench to bedside. Baltimore, Williams and Wilkins, 1994:5-30.
  4. M'Koma A.E. inflammatory bowel disease: an expanding global health problem. Clinical medicine insights: gastroenterology. 2013;6:33-47.
  5. Белоусова Е.А., Никитина Н.В., Цодикова О.М. Лечение язвенного колита легкого и среднетяжелого течения. Фарматека. 2013;2:42-6. [Belousova Ye.A., Nikitina N.V., Tsodikova O.M. Treatment of ulcerative colitis of mild to moderate currents. Pharmateca. 2013;2:42-6 (in Russ.)]
  6. Халиф И.Л. Лечебная тактика при язвенном колите. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2006;16(3):58-62. [Khalif I.L. Therapeutic strategy for ulcerative colitis. Russ. J. Gastroenterol. Hepatol. Coloproctol. 2006;16(3):58-62 (in Russ.)]
  7. Халиф И.Л. Принципы лечения язвенного колита (рекомендации российской группы по изучению воспалительных заболеваний кишечника). Колопроктология. 2006;2:31-3. [Khalif I.L. Principles of treatment of ulcerative colitis (recommendations of the Russian group for the study of inflammatory bowel disease). Coloproctology. 2006;2:31-3 (in Russ.)]
  8. Dignass A., Lindsay J.O., Sturm A. et al. 2nd European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 2: Current management Journal of Crohn's and Colitis. 2012;6:991-1030.
  9. Langholz E., Munkholm P., Davidsen M., Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107:3-11.
  10. Michelassi F., Fichera A., Kirshner J.B. Inflammatory bowel disease. 5th ed. Philadelphia, 2000:616-26.
  11. Воробьев Г.И., Халиф И.Л. Неспецифические воспалительные заболевания кишечника. М.: Миклош, 2008. 400 c. [Vorob'ev G.I., Khalif I.L. Non-specific inflammatory bowel disease. Moscow: Miklosh, 2008. 400 p. (in Russ.)]
  12. Князев О.В., Чурикова А.А. Антицитокиновая терапия и качество жизни больных воспалительными заболеваниями кишечника. Доказательная гастроэнтерология. 2014;2:17-23. [Knyazev O.V., Churikova A.A. Anticytokine therapy and quality of life in patients with inflammatory bowel disease. Evidence-based gastroenterology. 2014;2:17-23 (in Russ.)]
  13. Travis S.P., Stange E.F., Lemann M., Oresland T., Bemelman W.A., Chowers Y., Colombel J.F., D'Haens G., Ghosh S., Marteau P., Kruis W., Mortensen N.J., Penninckx F., Gassull M. European evidence-based consensus on the management of ulcerative colitis: current management. J. Crohns. Colitis. 2008;2:24-62.
  14. Ford A.C., Achkar J.P., Khan K.J., Kane SV, Talley NJ, Marshall JK, Moayyedi P. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am. J. Gastroenterol. 2011;106:601-16.
  15. Ham M., Moss A.C. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev. Clin. Pharmacol. 2012;5:113-23.
  16. Egan L.J., Sandborn W.J. Clinical pharmacology in inflammatory bowel disease: optimizing current medical therapy. In 2nd ed. London: Kluwer Academic publishers, 2002:495-522.
  17. D'Incà R., Paccagnella M., Cardin R., Pathak S., Baldo V., Giron M.C., Sturniolo G.C. 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis. World J. Gastroenterol. 2013;19(34):5665-70.
  18. Tenjarla S., Abinusawa A. In-vitro characterization of 5-aminosalicylic acid release from MMX mesalamine tablets and determination of tablet coating thickness. Adv. Ther. 2011;28:62-72.
  19. Tenjarla S., Romasanta V., Zeijdner E., Villa R., Moro L. Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system. Adv. Ther. 2007;24:826-40.
  20. Brunner M., Assandri R., Kletter K., Tschurlovits M., Corrado M.E., Villa R., Eichler H.G., Müller M. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol. Ther. 2003;17:395-402.
  21. LachaineJ., Yen L., Beauchemin C., Hodgkins P. Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients:analyses with the RAMQ database. BMC Gastroenterology. 2013;13:23.
  22. Kane S., Huo D., Aikens J., Hanauer S. Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. Am. J. Med. 2003;114(1):39-43.
  23. Kamm M.A., Lichtenstein G.R., Sandborn W.J., Schreiber S., Lees K., Barrett K., Joseph R. Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008;57:893-902.
  24. D'Haens G., Sandborn W.J., Feagan B.G., Geboes K., Hanauer S.B., Irvine E.J., Lémann M., Marteau P., Rutgeerts P., Schölmerich J., Sutherland L.R. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007;132(2):763-86.
  25. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 1987;317(26):1625-9.
  26. Travis S.P.L., Stange E.F., Lemann M., Oresland T., Bemelman W.A., Chowers Y., Colombel J.F., D'Haens G., Ghosh S., Marteau P., Kruis W., Mortensen N.J., Penninckx F., Gassull M. European evidence-based consensus on the management of ulcerative colitis: current management. J. Crohn. Colitis. 2008;2:24-62.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies